Apple, Masimo smartwatch spat ends in mistrial

Today's Big News

May 3, 2023

Beating its rivals, GSK nabs world-first approval for adult RSV vaccine Arexvy


Lilly's Alzheimer's win looks like a runaway, but data is more comparable to Leqembi on a deeper dive, analysts say


Apple, Masimo court case over smartwatch trade secrets ends in hung jury


Lilly's hotly anticipated Alzheimer's data set a new high score in slowing cognitive decline


Daewoong plots new $74.6M factory in South Korea to pump out Botox rival


Nanox scores clearance for cloud-connected X-ray bed after years of FDA review

 

Featured

Beating its rivals, GSK nabs world-first approval for adult RSV vaccine Arexvy

GSK is basking in "the golden age" of vaccine development with its newest shot, an exec said. Its next step will be to turn the recent approval into actual vaccinations, Dr. Leonard Friedland, vice president and director of scientific affairs and public health at GSK vaccines, said in an interview.
 

Top Stories

Lilly's Alzheimer's win looks like a runaway, but data is more comparable to Leqembi on a deeper dive, analysts say

The headline number from Eli Lilly’s Alzheimer’s data showing a 36% slowing of cognitive decline may have grabbed eyes, but analysts see a more even comparison with Biogen and Eisai’s Leqembi when you dig a little deeper.

Apple, Masimo court case over smartwatch trade secrets ends in hung jury

A jury was unable to come to a unanimous decision in a trial to determine whether Apple infringed on health-tracking technologies originally developed by fellow wearable maker Masimo.

Lilly's hotly anticipated Alzheimer's data set a new high score in slowing cognitive decline

Eli Lilly’s Alzheimer’s disease candidate has achieved a 35% slowing of cognitive decline and a 39% lower risk of advancing to the next stage of the disease when compared to placebo.

Daewoong plots new $74.6M factory in South Korea to pump out Botox rival

South Korea’s Daewoong Pharmaceutical plans to invest 100 billion South Korean won ($74.6 million) to build a third plant to produce its botulinum toxin product Nabota to meet increasing global demand.

Nanox scores clearance for cloud-connected X-ray bed after years of FDA review

Nanox has secured a long-awaited clearance from the FDA for its multi-source X-ray bed, designed to operate as a smaller, lighter imaging system in clinics and hospitals.

As Amgen's revenues slide, so too do sales at its big buyout target Horizon

In potentially the last quarter that Horizon Therapeutics will stand on its own, the rare disease drugmaker saw total sales slide by 6% as its biggest drug Tepezza falls 19% in year-over-year sales.

Cerevel to change up CEO as 7 data readouts near showdown

Four years after taking the helm of Cerevel Therapeutics, Tony Coles, M.D., is stepping down, handing the reins over to Ron Renaud as the neuroscience biotech waits on seven data readouts.

Akili's therapeutic video game improves ADHD symptoms in 83% of adults: study

Though it’s currently cleared by the FDA to lessen ADHD symptoms only in children between the ages of 8 and 12, Akili Interactive’s EndeavorRx digital therapeutic may actually be even more effective among older users.

Neurocrine gives up on Parkinson's drug Ongentys, citing 'unsustainable' launch

Even though Nuerocrine Biosciences has had great success with one neurological disorder drug, Ingrezza, it has struggled with Parkinson’s disease med Ongentys. Now, the company has decided to call it quits on the latter medicine.

Mini heart pump maker Magenta Medical collects $55M

The proceeds are slated for further clinical development with the goal of securing a U.S. approval.

Sarepta, days out from critical FDA meeting, lists questions expected at gene therapy AdComm

The clock is ticking down to the FDA advisory committee meeting about Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy SRP-9001. With days to go, Sarepta has set out what is expected to be asked at the meeting—and made the case that it can allay concerns about its confirmatory trial. 
 
Fierce podcasts

Don't miss an episode

'The Top Line': A series on Narcan, plus this week's headlines

This week on "The Top Line," we're launching a mini-series on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription.

 

Resources

eBook

Decentralized Clinical Trials: The Complete Guide for 2023

Discover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success.
Research

How Lilly’s Legal and Library Services Empower Teams Across the Drug Development Pipeline

What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how.
Whitepaper

Medical Affairs Metamorphosis VI: The Changing Face of Stakeholder Engagement

This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing.
Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies
Whitepaper

eConsent: Flexible Consent Through Enabling Technologies

How can eConsent provide a more flexible approach to informed consent?
Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

1-3
May
May 1-3, 2023 | Jersey City, NJ
12-14
Jun
San Diego, CA
13
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event
22
Jun
Free Virtual Event

View all events